Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives

Acute myeloid leukemia (AML) with NPM1 gene mutations is currently recognized as a distinct entity, due to its unique biological and clinical features. We summarize here the results of published studies investigating the clinical application of minimal/measurable residual disease (MRD) in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Forghieri, Fabio, Comoli, Patrizia, Marasca, Roberto, Potenza, Leonardo, Luppi, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274702/
https://www.ncbi.nlm.nih.gov/pubmed/30404199
http://dx.doi.org/10.3390/ijms19113492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274702/
https://www.ncbi.nlm.nih.gov/pubmed/30404199
http://dx.doi.org/10.3390/ijms19113492

Ejemplares similares